HIV Ag-Ab Multiplex Panel

  • HIV Multiplex Screening Assay

    The BioPlex™ 2200 HIV Ag-Ab Panel utilizes the power of multiplex technology to differentiate HIV (Human Immunodeficiency Virus) antigen and antibodies within a single test to give you four different results:

    • HIV Ag-Ab (Composite)
    • HIV-1 p24 Ag
    • HIV-1 Ab (Groups M & O)
    • HIV-2 Ab

    Contact a Specialist

  • BioPlex 2200 HIV Ag-Ab panel cartridge

This product is offered in certain areas. In some instances, there may be limited regional availability. If you have a specific question about our BioPlex 2200 solutions, please contact your local sales office or representative.

 
 

  • Don't Miss Our Labroots Webinar

    HIV Diagnostic Testing in the COVID-19 Era… Are Clinical Laboratories Being Overly SENSITIVE?

    This webinar will explore the current state of HIV diagnostic testing and discuss several studies detailing SARS-CoV-2 infection and vaccine cross-reactivity, along with the longitudinal specificity of the BioPlex 2200 HIV Ag-Ab Panel.

    Watch the webinar

  • Guest Speakers

    image of Anne-Genevieve Marcelin

    Tom Alexander, PhD
    FlowMetric Diagnostics
    Clinical Laboratory Director

    image of Jean-François Mouscadet

    Alfredo Villarreal, MBA
    Bio-Rad Clinical Immunology
    Global Product Manager

    images of Heidi Scholz

    Payu Raval, MD
    NorthShore University HealthSystem
    Pathology Resident

  • “The ability to differentiate HIV antigen and antibody results in screening tests could enable improved testing algorithms that will reduce the time to confirmation and ultimately improve clinical care.”

    Tom S. Alexander, PhD, D(ABMLI)
    Clinical Laboratory Director,
    FlowMetric Diagnostics and Consultant at Summit Pathology Associates

BioPlex 2200 HIV Ag-Ab Panel

More Results. More Information. Better Patient Management.

  • BioPlex HIV Ag-Ab infographic 5

  • The Power of Multiplex Technology

    The BioPlex 2200 HIV Ag-Ab Panel harnesses the power of multiplex technology to detect and differentiate HIV-1 p24 antigen, HIV-1 antibody, and HIV-2 antibody in a single test. Differentiation of p24 antigen allows the BioPlex 2200 HIV Ag-Ab Panel to identify acute HIV infections in a single screening test, prior to the rise in antibody levels and before confirmation testing.

    Detecting HIV early and differentiating HIV-1 p24 antigen, HIV-1 antibody, and HIV-2 antibody can help diagnose and treat patients earlier and reduce the transmission of HIV.

 

Differentiate p24 Antigen to Identify Acute HIV Infection

  • HIV-1 p24 antigen is a marker to improve early detection of HIV and to identify acute HIV infection. The BioPlex 2200 HIV Ag-Ab Panel differentiates HIV-1 p24 antigen from HIV-1 antibody and HIV-2 antibody.

    Acute HIV infection involves a rapid rise of virus levels prior to the immune system’s development of antibodies (see kinetics graph). High levels of HIV virus are associated with a greater likelihood of individuals transmitting the disease. So, it is extremely important to identify the acute phase of HIV infection as early as possible.

  • Traditional 4th Generation HIV tests do not differentiate the detection of HIV-1 p24 antigen from antibodies and therefore cannot distinguish an acute HIV infection.

    The value of the BioPlex 2200 HIV Ag-Ab Panel is that it detects HIV-1 p24 antigen, alerting diagnosticians to expedite confirmation testing so that patients begin treatment sooner and modify risk behaviors to prevent further transmission.

HIV Infection — Antigen and Antibody Kinetics

BioPlex HIV Ag-Ab infographic 6
 

Earliest Identification of Acute HIV Infection

This seroconversion panel (ZeptoMetrix) comparison testing shows that the BioPlex 2200 Ag-Ab Panel detects HIV before reference 4th generation tests, while also differentiating p24 antigen to help identify potential acute HIV infection.


Testing Day

BioPlex HIV Ag-Ab Panel1

HIV-1 p24 Ag HIV-1 Ab HIV-2 Ab

Competitor 12
4th Generation

Competitor 23
4th Generation

Nucleic Acid
Testing2 (NAT)*

0
Negative Negative Negative
Negative Negative Not Detected

2
Negative Negative Negative
Negative Negative Not Detected

7
Negative Negative Negative
Negative Negative Not Detected

9
Negative Negative Negative
Negative Negative Not Detected

14
Negative Negative Negative
Negative Negative Not Detected

16
Negative Negative Negative
Negative Negative Not Detected

21
Negative Negative Negative
Negative Negative 2,000

23
Positive Negative Negative
Negative Negative 44,700

28
Positive Negative Negative
Positive Positive >750,000

33
Positive Positive Negative
Positive Positive >750,000

35
Positive Positive Negative
Positive Positive >750,000

40
Positive Positive Negative
Positive Positive 143,000

42
Negative Positive Negative
Positive Positive Not Detected

* Units in copies/mL

 

Advantages of Early HIV-1 p24 Detection 

  • Presumptively indicate the most infectious phase of an HIV infection to prevent further transmission
  • Patients begin antiretroviral therapies sooner
  • Aid in the selection of appropriate confirmatory testing

  • Minimizes False-Positive Results

    Current HIV testing algorithms may require multiple tests to confirm HIV positive screening results. Confirmation testing is costly and time consuming, so minimizing false-positive results is very important. SARS-CoV-2 infections and vaccinations may cause interference or cross-reactivity on highly sensitive HIV immunoassays, resulting in false-positive results.

    The BioPlex 2200 HIV Ag-Ab Panel has excellent specificity, demonstrated by long-term longitudinal studies,4 and has shown no interference from cross-reactivity studies with SARS-CoV-2.5 The benefit is fewer false-positive results, resulting in less effort and cost from performing unnecessary confirmatory testing.

  • BioPlex HIV Ag-Ab infographic 7
 

More Results, Less Effort.

The BioPlex 2200 HIV Ag-Ab Panel generates multiple HIV antigen and antibody results in a single test.

check mark icon

Guides Algorithm Testing

Differentiation of HIV-1 p24 antigen, HIV-1 antibody, and HIV-2 antibody indicates how testing algorithms can provide appropriate confirmation for acute or latent HIV infections

check mark icon

Detects Acute HIV Infection Earlier

Highly sensitive detection and differentiation of HIV-1 antigen provides the earliest indication of an acute HIV infection, minimizing transmission of HIV infection and allowing for critical initiation of treatment

check mark icon

Reduces False-Positive Results

Highly specific results reduces the number of false-positive results to minimize time-consuming and costly confirmation tests

BioPlex 2200 System

  • bioplex 2200
  • bead tree
  • streamline bioplex
  • turnaround times
  • tla system
  • lis bioplex
BioPlex 2200 HIV Ag-Ab Panel

HIV (Human Immunodeficiency Virus)

BioPlex 2200 HIV Ag-Ab Panel

For simultaneous qualitative detection and differentiation of three HIV analytes plus a composite.

Aids in the diagnosis of infection with HIV-1 and/or HIV-2, including acute (primary) HIV-1 infection along with infection with HIV-1 and/or HIV-2 in pediatric subjects as young as two years of age, and pregnant women.

  • HIV Ag-Ab (Composite)
  • HIV-1 p24 Ag
  • HIV-1 Ab (Groups M & O)
  • HIV-2 Ab

Please contact your local sales office for any product questions.

References

  1. Bio-Rad Laboratories, BioPlex 2200 HIV Ag-Ab Instructions for Use.
  2. ZeptoMetrix Corporation (2019). HIV Seroconversion Panel Donor No. 73698, Part Number HIV12008. 1–2.
  3. Data on file at investigating laboratory.
  4. Bio-Rad Laboratories, BioPlex 2200 HIV Ag-Ab Instructions for Use.
  5. Villarreal A et al. (2022). Longitudinal Specificity in a US Public Health Laboratory. Presented at the 35th Association of Medical Laboratory Immunologists (AMLI) annual meeting.
  6. Raval P (2022). Does COVID-19 affect HIV assays? Presented at the 35th Association of Medical Laboratory Immunologists (AMLI) annual meeting.